Cargando…

Osimertinib in Indian patients with T790M-positive advanced nonsmall cell lung cancer

Detalles Bibliográficos
Autores principales:	Noronha, Vanita, Majumdar, Swaratika, Joshi, Amit, Patil, Vijay, Trivedi, Vaishakhi, Chougule, Anuradha, Prabhash, Kumar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2017
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5763619/ https://www.ncbi.nlm.nih.gov/pubmed/29404287 http://dx.doi.org/10.4103/sajc.sajc_202_17

Ejemplares similares

Osimertinib for lung cancer cells harboring low-frequency EGFR T790M mutation
por: Joshi, Asim, et al.
Publicado: (2022)

Third-line therapy in the epidermal growth factor receptor mutation-positive advanced nonsmall-cell lung cancer
por: Noronha, Vanita, et al.
Publicado: (2020)

Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis
por: Kate, Shruti, et al.
Publicado: (2019)

Sequential treatment with alectinib in crizotinib-resistant non-small-cell lung cancer
por: Majumdar, Swaratika, et al.
Publicado: (2018)

ROS1 mutation non-small cell lung cancer—access to optimal treatment and outcomes
por: Joshi, Amit, et al.
Publicado: (2019)

Treatment pattern and outcomes in de novo T790M-mutated non-small cell lung cancer
por: Panda, Goutam Santosh, et al.
Publicado: (2022)

Lorlatinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: Indian experience
por: Talreja, Vikas T., et al.
Publicado: (2020)

A cross-sectional observation study regarding patients and their physician willingness to wait for driver mutation report in nonsmall-cell lung cancer
por: Joshi, Amit, et al.
Publicado: (2016)

The Importance of Brain Metastasis in EGFR Mutation Positive NSCLC Patients
por: Noronha, Vanita, et al.
Publicado: (2014)

Thromboembolic events in patients with advanced stage non-small cell lung cancer treated with platinum-based chemotherapy: a prospective observational study
por: Joshi, Amit, et al.
Publicado: (2018)

Lung cancer in the Indian subcontinent
por: Noronha, Vanita, et al.
Publicado: (2016)

Use of lorlatinib subsequent to crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: Indian experience
por: Talreja, Vikas T., et al.
Publicado: (2019)

Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?
por: Joshi, Amit, et al.
Publicado: (2018)

Weekly osimertinib dosing prevents EGFR mutant tumor cells destined to home mouse lungs
por: Butle, Ashwin, et al.
Publicado: (2021)

Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer: Retrospective Data Analysis from an Indian Centre
por: Noronha, Vanita, et al.
Publicado: (2016)

Phase III Non-inferiority Study Evaluating Efficacy and Safety of Low Dose Gemcitabine Compared to Standard Dose Gemcitabine With Platinum in Advanced Squamous Lung Cancer
por: Patil, Vijay, et al.
Publicado: (2019)

Frequency of EGFR Mutations in 907 Lung Adenocarcioma Patients of Indian Ethnicity
por: Chougule, Anuradha, et al.
Publicado: (2013)

EGFR mutation in squamous cell carcinoma of the lung: does it carry the same connotation as in adenocarcinomas?
por: Joshi, Amit, et al.
Publicado: (2017)

EGFR Mutations in Indian Lung Cancer Patients: Clinical Correlation and Outcome to EGFR Targeted Therapy
por: Noronha, Vanita, et al.
Publicado: (2013)

ALK Positive Lung Cancer: Clinical Profile, Practice and Outcomes in a Developing Country
por: Noronha, Vanita, et al.
Publicado: (2016)

Molecular characterization of lung squamous cell carcinoma tumors reveals therapeutically relevant alterations
por: Joshi, Asim, et al.
Publicado: (2021)

Clinical Profile, Practice Pattern, and Outcomes With First-Line Therapy in ALK-Positive Lung Cancer: Real-World Data From Resource-Constrained Settings
por: Kapoor, Akhil, et al.
Publicado: (2022)

Real-World Experience of Patients with Inoperable, Stage III Non-small-Cell Lung Cancer Treated with Durvalumab after Chemoradiotherapy: Indian Experience
por: Noronha, Vanita, et al.
Publicado: (2020)

Maintenance pemetrexed in nonsmall cell lung carcinoma: Outcome analysis from a tertiary care center
por: Pandey, Avinash Vijaykumar, et al.
Publicado: (2015)

Impact of apatinib in combination with osimertinib on EGFR T790M-positive lung adenocarcinoma
por: Liu, Yang, et al.
Publicado: (2019)

Primary resistance to osimertinib despite acquired T790M
por: Chang, Ling‐Kai, et al.
Publicado: (2020)

An exceptional response to olaparib in relapsed and refractory BRCA2 mutated non-small cell lung cancer in hereditary breast–ovarian cancer syndrome
por: Talreja, Vikas T., et al.
Publicado: (2020)

Rapid intracranial response to osimertinib, without radiotherapy, in nonsmall cell lung cancer patients harboring the EGFR T790M mutation: Two Case Reports
por: Koba, Taro, et al.
Publicado: (2017)

Abivertinib in patients with T790M‐positive advanced NSCLC and its subsequent treatment with osimertinib
por: Wang, Hanping, et al.
Publicado: (2020)

ADME gene polymorphisms do not influence the pharmacokinetics of docetaxel: Results from a population pharmacokinetic study in Indian cancer patients
por: Patil, Anand, et al.
Publicado: (2021)

Excellent response to oral Metronomic chemotherapy in unresectable adenocarcinoma of external auditory canal
por: Noronha, Vanita, et al.
Publicado: (2015)

An exceptional response to nivolumab in relapsed and refractory malignant mesothelioma
por: Talreja, Vikas T., et al.
Publicado: (2019)

Osimertinib administration via nasogastric tube in an EGFR‐T790M‐positive patient with leptomeningeal metastases
por: Takeda, Takayuki, et al.
Publicado: (2017)

Osimertinib as an emerging therapeutic modality in nonsmall cell lung cancer: Opportunities and challenges in Indian scenario
por: Thakur, Sayanta, et al.
Publicado: (2020)

EGFR mutation genotypes affect efficacy and resistance mechanisms of osimertinib in T790M-positive NSCLC patients
por: Zheng, Qiufan, et al.
Publicado: (2020)

An observational study to evaluate factors predicting survival in patients of non-small cell lung cancer with poor performance status in resource-constrained settings
por: Kapoor, Akhil, et al.
Publicado: (2021)

Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?
por: Joshi, Amit, et al.
Publicado: (2017)

Extra-lymphatic filariasis at reconstructive surgery flap site recurrence of head and neck cancer
por: Shetty, Nishitha, et al.
Publicado: (2015)

Epidermal growth factor receptor exon 20 mutation in lung cancer: types, incidence, clinical features and impact on treatment
por: Noronha, Vanita, et al.
Publicado: (2017)

Small cell carcinoma of the oesophagus: experience of an Indian Tertiary Cancer Centre
por: Panda, Goutam Santosh, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vuka128tsordqkkp5om00hisip